According to WHO, as of March 20, two vaccine candidates were in Phase I clinical trial, and 42 others were in preclinical development. This information is supplemented by an April 7, 2020 Motley Fool article with more recent developments, which is focused on vaccine trials by companies with at least $200 million in market capitalization. According to the Fool, many companies, “had vaccine platforms targeting other coronaviruses such as MERS and SARS. This enabled them to rapidly prototype experimental vaccines for immunizing against the novel coronavirus that causes COVID-19.” The article lists 12 companies with products in development with the designated market cap, one clinical and 11 pre-clinical.
INOVIO Uses DNA Plasmids in COVID-19 Vaccine Trial
One late-breaking study that did not make the WHO list is by INOVIO. In a press release from April 6, they announced that the FDA had approved the application for its DNA vaccine “INO-4800” with first Phase I dosing to begin that day. The INOVIO research is being conducted in, “Philadelphia, PA (at the Perelman School of Medicine at the University of Pennsylvania) and Kansas City, MO (at the Center for Pharmaceutical Research)...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).